Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
Approximately 1 million individuals are living with multiple sclerosis in the United States, according to the National MS Society.
Delayed-release oral capsules for various forms of the disease.
Psoriasis, MS, Lupus, and RA.
Current phase 3 studies investigative novel, preventative approaches.
The next-generation oral drug is the first to be approved specifically for secondary progressive multiple sclerosis in more than 15 years.